Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1086846 | 0.79 | TSHR (0.43) | SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4263516 | 0.79 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1LMNAKMT2APOLB | |
| SCHEMBL1085855 | 0.78 | RIPK1 (0.49) | ALDH1A1KMT2APOLBMEN1 | |
| SCHEMBL1086544 | 0.78 | TSHR (0.38) | SMN1; SMN2POLB | |
| SCHEMBL1085948 | 0.77 | POLB (0.46) | SMN1; SMN2ALDH1A1LMNAKMT2APOLB | |
| SCHEMBL1086697 | 0.76 | HTT (0.44) | ALDH1A1POLBHTT | |
| SCHEMBL4257384 | 0.76 | LMNA (0.38) | SMN1; SMN2ALDH1A1LMNAKMT2APOLB | |
| SCHEMBL13078736 | 0.75 | TACR2 (0.53) | KMT2AMEN1 | |
| SCHEMBL1086607 | 0.75 | TSHR (0.47) | SMN1; SMN2ALDH1A1LMNAKDM4EGAA | |
| SCHEMBL1086332 | 0.75 | POLB (0.46) | SMN1; SMN2ALDH1A1LMNAKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153795-B2 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs | GRUENENTHAL GMBH (DE) | 2012-04-10 | — | — | US | claimed |
| EP-1910381-B1 | SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2009-06-03 | — | — | EP | claimed |
| US-20090105290-A1 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs | GRUENENTHAL GMBH (DE) | 2009-04-23 | — | — | US | claimed |
| US-8153795-B2 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs | GRUENENTHAL GMBH (DE) | 2012-04-10 | — | — | US | disclosed |
| EP-1910381-B1 | SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-20090105290-A1 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs | GRUENENTHAL GMBH (DE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105290-A1 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs | DDO, DAO, OTC | SMN1; SMN2 3067/4885RECQL 2786/4885ALDH1A1 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.